Magnesium L-Threonate (MgT) for Parkinson's Disease
Also known as: MgT, Magtein, MMFS-01
Magnesium deficiency is associated with increased Parkinson's risk, and MgT may support dopaminergic neuron survival through NMDA modulation.
Mechanism of Action
MgT elevates brain Mg²⁺ to modulate NMDA receptor overactivation in basal ganglia circuits, supports mitochondrial function through Mg²⁺-dependent enzyme activation, and may reduce α-synuclein-induced excitotoxicity.
General mechanism: BBB-penetrant magnesium salt. Elevates brain Mg²⁺ for NMDA receptor modulation, synaptic density enhancement, BACE1 suppression.
Current Evidence
Epidemiological data links higher dietary Mg²⁺ with reduced PD risk. No clinical trials with MgT for PD. Mechanistic rationale from neuroprotection studies.
Clinical Status: No PD-specific trials. Epidemiological support for Mg²⁺ in PD prevention.
Safety Profile
Very safe. Mild GI effects. No significant interactions. Well-tolerated at recommended doses.
Key Research Questions
- Can MgT supplementation reduce PD risk in at-risk populations?
- Does brain Mg²⁺ elevation protect substantia nigra neurons?